title: Pharmacokinetics of xamoterol after intravenous and oral administration to volunteers.
abstract: The pharmacokinetics of xamoterol, a beta-adrenoceptor partial agonist under clinical evaluation for the treatment of mild to moderate heart failure, have been studied in 12 healthy male subjects. They received 14 mg i.v. and oral doses of 50 and 200 mg as a tablet and 200 mg as a solution in a 4 way cross-over design. After i.v. dosing the elimination half-life was 7.7 h, the total body clearance was 224 ml.min-1 and the volume of distribution at steady-state (Vss) was 48 l. Sixty-two percent of the dose was recovered unchanged in urine. After oral doses, the absolute bioavailability of xamoterol was shown to be 5% irrespective of whether the dose was administered as a tablet or solution. Peak plasma concentrations occurred at about 2 h for the tablet dose and slightly earlier (1.4 h) for the solution. Peak plasma concentration, AUC and urinary recovery of unchanged drug increased in proportion to dose. The apparent elimination half-life after oral doses (16 h) was significantly longer than that observed after an intravenous dose. Despite the low bioavailability, the degree of inter-subject variability of oral bioavailability was small probably indicating that the controlling factor is the hydrophilic nature of the molecule rather than extensive first pass metabolism or poor dissolution of xamoterol from the tablet formulation.
authors.affiliation: Clinical Pharmacology Unit, Imperial Chemical Industries PLC, Pharmaceuticals Division, Macclesfield, Cheshire, UK.
authors.forename: W
authors.initials: W
authors.lastname: Bastain
authors.forename: M J
authors.initials: MJ
authors.lastname: Boyce
authors.forename: L E
authors.initials: LE
authors.lastname: Stafford
authors.forename: P B
authors.initials: PB
authors.lastname: Morton
authors.forename: D A
authors.initials: DA
authors.lastname: Clarke
authors.forename: H F
authors.initials: HF
authors.lastname: Marlow
mesh_terms: D000284:Administration, Oral; D000318:Adrenergic beta-Agonists / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000494:pharmacology; D000328:Adult; D001682:Biological Availability; D001794:Blood Pressure / Q000187:drug effects; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D011412:Propanolamines / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000494:pharmacology; D011485:Protein Binding; D017307:Xamoterol
chemical_list: D000318:Adrenergic beta-Agonists; D011412:Propanolamines; D017307:Xamoterol